Trial of Lixisenatide in Early Parkinson's Disease
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, +2 more
New England Journal of Medicine (2024) · n=156
Lixisenatide-treated patients showed no motor decline at 12 months while placebo-treated patients worsened by 3.04 MDS-UPDRS-III points — a 3.08-point between-group separation (p=0.0068) that is the first positive primary endpoint for a GLP-1 agonist in early Parkinson's disease.
LIXIPARK is the Phase 2 randomized controlled trial that tested the GLP-1 receptor agonist lixisenatide in early, treated Parkinson's disease. Meissner and colleagues at 21 French centers randomized 156 patients diagnosed within the prior three years and on stable symptomatic dopaminergic therapy in a 1:1 ratio to daily subcutaneous lixisenatide (20 µg) or matching placebo for 12 months, followed by a two-month washout. The primary endpoint was change from baseline in the Movement Disorder Society Unified Parkinson's Disease Rating Scale part III (motor) assessed in the on-medication state at month 12.
At month 12, MDS-UPDRS-III scores worsened by 3.04 points (95% CI, 1.46 to 4.62) in the placebo arm and changed by -0.04 points (95% CI, -1.62 to 1.54) in the lixisenatide arm — a between-group difference of 3.08 points (95% CI, 0.86 to 5.30; p=0.0068) favoring lixisenatide. Off-medication motor scores after washout also favored the active arm, which the investigators interpreted as compatible with — but not proof of — a disease-modifying rather than symptomatic effect. Gastrointestinal adverse events were the dominant tolerability signal, occurring in approximately half of lixisenatide recipients (nausea, vomiting, reflux); few patients discontinued for tolerability. The trial was sponsored by Toulouse University Hospital with funding from the French Ministry of Health and Cure Parkinson's; Sanofi supplied active drug and placebo but did not participate in design or analysis.
LIXIPARK is the second positive Phase 2 readout in the GLP-1 / Parkinson's-disease literature, following the exenatide signal in the Athauda 2017 PD3 trial. The two trials together — with different molecules and different study groups — have shifted the field from "intriguing mechanism" to "warrants confirmatory Phase 3," though as of 2026 no such trial has read out. The negative McGarry et al. 2024 NLY01 (pegylated exenatide) result and the negative Phase 3 exenatide-once-weekly readout from the UCL group both complicate the narrative; the broader dossier is summarized at Parkinson's and peptides.
The headline magnitude — three MDS-UPDRS-III points — is statistically significant but clinically modest, and the minimal clinically important difference for MDS-UPDRS-III in early PD is debated (estimates range from 3.25 to 4.6 points in the published literature). A 3.08-point separation sits at or below most published MCID thresholds. The off-state washout signal is hypothesis-generating rather than confirmatory; the trial was not powered or designed to demonstrate disease modification, and the 12-month plus 2-month washout duration is too short for that question.
The choice of comparator and dose deserves attention. Lixisenatide was used at the diabetes-approved 20 µg daily subcutaneous dose; no dose-ranging was performed in PD. Sanofi withdrew lixisenatide from most diabetes markets in 2023 and now distributes it only as a fixed insulin-lixisenatide combination unsuitable for PD use, which means any confirmatory Phase 3 program would require Sanofi commitment or a regulatory pathway to compounded lixisenatide — neither announced as of 2026.
Tolerability is the practical concern. Roughly half the active arm reported nausea or vomiting; in a non-diabetic, often older PD population without the metabolic counterweight that motivates GI tolerability in diabetes patients, the adverse-event ceiling for chronic use is unclear. The trial enrolled predominantly White French patients with a relatively narrow disease duration window (within 3 years of diagnosis); generalizability to longer-duration, levodopa-complicated, or non-European populations is unestablished. Industry sponsorship is limited to drug supply, which strengthens rather than weakens the result. Replication in a confirmatory trial is the natural next step but has not occurred at the time of writing.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.